Wall Street is hovering around record highs as a couple of high-profile companies reported their latest quarterly earnings.
The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...